|
Patent landscape, scope, and claims: |
US Patent 8,648,106 Landscape, Claim Scope, and Design-Around Targets for Ready-to-Use Dexmedetomidine Parenteral Liquids
Executive summary: US Patent 8,648,106 covers a ready-to-use parenteral liquid containing dexmedetomidine (or a pharmaceutically acceptable salt) in a sealed glass container, where at least five months storage produces no more than ~2% decrease in dexmedetomidine concentration. Independent claim 1 is anchored on the container type (sealed glass) and a stability performance threshold. Dependent claims narrow to specific dexmedetomidine concentration ranges (broad, mid, and preferred subranges), optional sodium chloride at ~0.01 to 2.0 wt% (including ~0.9 wt%), and fill volumes (20, 50, 100 mL). The competitive risk for a generic or competitor is highest for products that match the same container format and stability specification; lower if they use different container systems (plastic, different glass treatment, cartridges/containers not matching “sealed glass”), different end-of-shelf/hold testing targets, or different concentration outside the claimed bands.
What does US Patent 8,648,106 claim cover for ready-to-use dexmedetomidine injections?
Featured snippet answer: US 8,648,106 claims a ready-to-use dexmedetomidine parenteral liquid in a sealed glass container that maintains ≤ about 2% loss of dexmedetomidine concentration after at least five months storage.
Claim 1 scope (independent) mapped to enforceable claim elements
Claim 1 elements (structure, material, performance, and use context):
- “Ready to use liquid pharmaceutical composition for parenteral administration”
- Dexmedetomidine or pharmaceutically acceptable salt
- “Disposed within a sealed glass container”
- Performance/stability requirement: when stored in the glass container for at least five months, the composition shows no more than about 2% decrease in dexmedetomidine concentration.
Practical enforcement implications
- The claim is not limited to a particular dosing regimen, method of use, or patient population. It is framed around composition + container + stability outcome.
- The stability clause is a functional limitation. A court or PTAB will examine whether an accused product meets the measured concentration decrease criterion under comparable storage conditions.
- The “sealed glass container” language is the principal structural barrier for design-around. If a product uses non-glass containers, unsealed systems, or glass formats not meeting the “sealed” condition as construed, it may fall outside claim 1.
Claim 1 likely construed terms (high-impact)
- “Ready to use”: typically means no reconstitution and no compounding by the end user (e.g., clinically used as a prepared injectable). If an accused product requires dilution/reconstitution, it may not meet this limitation.
- “Sealed glass container”: the container likely includes glass vials/syringes/infusion containers that are sealed (e.g., stopper + crimp, or syringe closure) such that the internal liquid is contained without open exposure.
- “About 2% decrease”: permits measurement and rounding. In litigation, the exact analytical method and sampling points matter.
How do the concentration limits in claims 2-6 narrow dexmedetomidine coverage?
Featured snippet answer: Claims 2-6 carve out several dexmedetomidine concentration bands, ranging from 0.005 to 50 ug/mL (claim 2) down to narrower ranges, including a specific 4 ug/mL example.
Dependent claim concentration bands
| Claim |
Dexmedetomidine (free base or salt) concentration (ug/mL) |
Claim wording implication |
| 2 |
0.005 to 50 |
Very broad concentration coverage; captures many plausible dilute-to-therapeutic ranges |
| 3 |
0.05 to 15 |
Mid-range coverage; excludes extreme low and high ends |
| 4 |
0.5 to 10 |
Concentration band typical for many infusion/ready-dose formulations |
| 5 |
1 to 7 |
Narrower middle band |
| 6 |
about 4 |
A specific embodiment; can create strong infringement leverage if an accused product is at/near this point |
Litigation exposure driven by concentration selection
- If a competitor formulates at 0.005–50 ug/mL, they remain within the broadest claimed concentration range (claim 2).
- If they choose outside 0.005–50, they are outside all listed concentration-dependent claims, but may still risk independent claim 1 depending on how “dexmedetomidine concentration” is handled in claim 1 (claim 1 itself does not state a concentration range). In other words, claim 1 may still read on other concentrations because it is concentration-agnostic, provided the stability outcome and container constraints are met.
What does the sodium chloride limitation in claims 7-8 mean for formulation design?
Featured snippet answer: Claims 7 and 8 add an optional excipient limitation: sodium chloride at 0.01–2.0 wt%, including a preferred embodiment at about 0.9 wt%.
Claim 7 and 8 scope
- Claim 7: sodium chloride 0.01 to 2.0 weight percent
- Claim 8: sodium chloride about 0.9 weight percent
Design-around leverage
- Removing sodium chloride or using a sodium source outside the claimed wt% band can avoid claims 7-8.
- However, avoidance of dependent claims does not necessarily avoid claim 1, since claim 1 does not require sodium chloride.
What fill volumes are protected under claim 9 for ready-to-use products?
Featured snippet answer: Claim 9 requires total volume selected from 20 mL, 50 mL, or 100 mL.
Claim 9 scope
- The composition is the same “ready-to-use” injectable liquid, but claim 9 adds a specific container volume limitation.
Practical implications for packaging changes
- Switching to other fill volumes (e.g., 10 mL, 25 mL, 30 mL) can avoid claim 9.
- Again, this does not negate independent claim 1 unless the alleged infringement strategy depends on volume-specific claims.
How does the five-month stability requirement drive infringement and validity analysis?
Featured snippet answer: The core technical hook is that after ≥ five months storage in a sealed glass container, the dexmedetomidine concentration falls by no more than ~2%.
Why this matters in patent disputes
- Stability outcomes are measurable. An accused product that shows ≤2% decrease in concentration after five months under relevant conditions can support infringement.
- Conversely, a competitor can try to:
- match the stability only at shorter timepoints, or
- demonstrate different degradation pathways, or
- show concentration decrease exceeds 2% under test conditions.
Likely test/assay variables that affect claim mapping
Even without introducing additional limitations not in the claim, stability assessments typically depend on:
- storage temperature and light conditions
- sampling timepoints (exactly “at least five months”)
- analytical assay method for dexmedetomidine concentration
- container headspace, stopper type, and closure configuration (as part of “sealed glass container”)
Legal consequence: functional claim element
A stability functional limitation creates:
- evidentiary needs in litigation (study reports, bench data, stability protocols)
- potential invalidity pressure if the claimed stability threshold is argued as not novel or not inventive over the prior art stability performance.
What prior art and novelty themes likely surround US 8,648,106’s stability-in-glass limitation?
Featured snippet answer: The novelty burden typically focuses on whether earlier patents or publications disclosed (i) dexmedetomidine parenteral liquids, (ii) in sealed glass containers, and (iii) storage stability results meeting the ≤2% loss after five months threshold.
High-probability prior-art disclosure categories
- Dexmedetomidine injectable formulations in glass (vials or syringes) with generic excipient systems.
- Stability studies of dexmedetomidine in glass packaging at multiple timepoints.
- Standard pharmacy ready-to-use formats (pre-diluted or prefilled).
Where the patent may still be strong
If the prior art does not explicitly provide:
- an outcome threshold like “no more than about 2% decrease” at five months, or
- a disclosed combination of “sealed glass container” and that specific stability performance,
then claim 1 can be positioned as a data-defined formulation-in-packaging invention.
What patent landscape exists around dexmedetomidine injectable liquids in the US?
Featured snippet answer: The US dexmedetomidine injectable patent landscape typically contains a mix of:
- composition/formulation patents,
- container and stability data patents,
- process/manufacturing patents, and
- method-of-use (clinical use) patents in broader anesthesia/sedation spaces.
How US 8,648,106 fits within that landscape
- This patent is best characterized as formulation-in-packaging with stability performance rather than a method-of-use claim.
- Its claim construction is likely to overlap with other patents in the space that protect:
- specific concentration ranges,
- excipient systems (e.g., saline),
- fill volumes,
- and stability in specific container-closure systems.
Competitive relevance for generics and biosimilar-style entrants
- Dexmedetomidine is a small molecule. The main “entry risk” is generic formulation and container/packaging for ANDA (if applicable) rather than biosimilar rules.
- A competitor’s risk is highest where they can’t change the container system or the stability performance is inherently achieved through their manufacturing approach.
What generic entry risks exist for dexmedetomidine liquids protected by US 8,648,106?
Featured snippet answer: The most direct generic entry risk comes from matching (a) sealed glass container format and (b) storage stability meeting the ≤2% loss after five months criterion.
Generic/competitor risk matrix by element
| Accused product element |
If it matches US 8,648,106 |
Likely infringement pressure |
| Ready-to-use parenteral liquid |
Yes |
Enables claim 1 framing |
| Dexmedetomidine (salt allowed) |
Yes |
Enables core active component match |
| Sealed glass container |
Yes |
High leverage for claim 1 |
| Stability: ≤ about 2% concentration decrease at ≥5 months |
Yes |
Core evidentiary hook |
| Dexmedetomidine concentration within 0.005–50 ug/mL |
Yes |
Increases dependent claim exposure |
| Sodium chloride at 0.01–2.0 wt% (or ~0.9%) |
Yes |
Adds dependent claim exposure |
| Fill volume 20/50/100 mL |
Yes |
Adds dependent claim exposure |
Design-around options that conceptually reduce claim mapping
- Use non-glass packaging or alter the container-closure system so it is not a “sealed glass container” as construed.
- Choose a formulation strategy that results in >2% concentration decrease after five months (or demonstrate that it does).
- Use a concentration outside the specific dependent bands, or select a fill volume outside 20/50/100 mL to avoid claims 2-6 and 9 (but claim 1 may remain).
How does US 8,648,106 compare with typical dexmedetomidine formulation patents?
Featured snippet answer: Compared with conventional formulation patents that claim ingredient lists or processes, US 8,648,106 is anchored on a measured stability outcome in sealed glass and therefore acts like a data-defined packaging-stability protection.
Key differences versus ingredient-only claims
- Ingredient-only patents are often avoided by changing excipients or concentration.
- Here, even if excipients change, the independent claim may still be implicated if the product remains:
- sealed glass-packaged, and
- stable enough to maintain ≤2% loss after ≥5 months.
Key differences versus container-only claims
- Container-only patents can be avoided with other closures or glass types.
- This patent ties container to a stability performance benchmark, increasing the chance that a “different glass” or “different seal” changes the stability outcome.
What does this claim set imply for Orange Book listing and FDA regulatory strategy?
Featured snippet answer: If US 8,648,106 is listed in the FDA Orange Book for dexmedetomidine products, FDA paragraph IV certifications would typically be assessed against claim 1’s stability-in-sealed-glass requirements, not only ingredient descriptions.
Regulatory strategy effects (commercial consequences)
- ANDA applicants typically must address listed patents with certifications. For a data-defined stability claim, the key issue becomes whether the proposed product:
- uses a sealed glass container,
- and meets the stability outcome at relevant timepoints.
Practical litigation posture this drives
- Patent owners often seek stability study evidence.
- Generic challengers often rely on differing container systems, different storage conditions, or proof that the proposed product does not meet the ≥5 month ≤2% stability criterion.
Key takeaways
- US 8,648,106 claim 1 protects a ready-to-use dexmedetomidine parenteral liquid packaged in a sealed glass container that retains ≤ about 2% concentration loss after at least five months.
- Dependent claims 2-6 add coverage across multiple dexmedetomidine concentration ranges (0.005–50 ug/mL down to about 4 ug/mL).
- Dependent claims 7-8 cover sodium chloride excipient levels 0.01–2.0 wt%, including ~0.9 wt%.
- Dependent claim 9 narrows to fill volumes of 20, 50, or 100 mL.
- The strongest infringement lever is the combination of sealed glass packaging and the five-month stability threshold; the strongest design-around lever is changing the container system and/or failing the ≤2% stability criterion after ≥5 months.
- The competitive and regulatory risk for generics hinges on whether the proposed product can avoid claim 1 mapping, not only whether it avoids dependent claim concentration, saline, or fill-volume limitations.
FAQs
1) Does US 8,648,106 require any specific excipient besides dexmedetomidine?
Claim 1 does not require sodium chloride or any other excipient. Sodium chloride is only added in dependent claims 7-8.
2) Can a product outside 20/50/100 mL still infringe US 8,648,106?
Yes. Avoiding claim 9 may avoid that dependent claim, but claim 1 can still be asserted if the product is a ready-to-use dexmedetomidine liquid in a sealed glass container meeting the five-month ≤2% stability requirement.
3) What is the most important design-around element for a competitor?
The highest-risk element is the “sealed glass container” tied to the ≤2% concentration decrease after ≥five months stability performance.
4) Do claims 2-6 limit infringement only to specific dosing strengths?
They limit the dependent claims, but claim 1 itself does not specify a concentration range, so an accused product can still fall under claim 1 even if it is outside one or more dependent bands.
5) Is this patent about method-of-use for dexmedetomidine?
No. The claims are composition and packaging/stability based for parenteral ready-to-use formulation, not a clinical method-of-use claim.
References
- US Patent 8,648,106.
More… ↓
⤷ Start Trial
|
